Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

20121,146 citationsJournal Articlebronze Open Access

Authors

Michel Attal · Hôpital Purpan

Valérie Lauwers‐Cancès · Hôpital Purpan

Gérald Marit · Hôpital Cardiologique du Haut-Lévêque

Denis Caillot · CHU Dijon Bourgogne

Philippe Moreau

Thierry Façon · Hôpital Claude Huriez

Anne Marie Stoppa · Institut Paoli-Calmettes

Abstract

Lenalidomide maintenance after transplantation significantly prolonged progression-free and event-free survival among patients with multiple myeloma. Four years after randomization, overall survival was similar in the two study groups. (Funded by the Programme Hospitalier de Recherche Clinique and others; ClinicalTrials.gov number, NCT00430365.).

Topics & Keywords

Multiple Myeloma Research and Treatments Protein Degradation and Inhibitors Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 366, Issue 19, pp. 1782-1791

DOI: 10.1056/nejmoa1114138

Field-Weighted Citation Impact: 68.58